GSK, Chroma in potential $1B deal over anti-inflammatory drugs

06/23/2009 | Reuters

GlaxoSmithKline is teaming up with Chroma Therapeutics to secure rights to the latter's small-molecule compounds that target macrophages to treat inflammatory diseases such as rheumatoid arthritis. Chroma could receive more than $1 billion out of the deal depending on the success of the four drug programs, which employ its proprietary esterase-sensitive motif technology to enhance drug delivery.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care